170 related articles for article (PubMed ID: 8585108)
1. Pharmacokinetic interaction between lansoprazole and theophylline.
Granneman GR; Karol MD; Locke CS; Cavanaugh JH
Ther Drug Monit; 1995 Oct; 17(5):460-4. PubMed ID: 8585108
[TBL] [Abstract][Full Text] [Related]
2. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
3. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
Pan WJ; Goldwater DR; Zhang Y; Pilmer BL; Hunt RH
Aliment Pharmacol Ther; 2000 Mar; 14(3):345-52. PubMed ID: 10735929
[TBL] [Abstract][Full Text] [Related]
4. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone.
Cavanaugh JH; Karol MD
J Clin Pharmacol; 1996 Nov; 36(11):1064-71. PubMed ID: 8973995
[TBL] [Abstract][Full Text] [Related]
6. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
7. Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers.
Barclay ML; Begg EJ; Robson RA; Peters WA; Ketelbey JW
Aliment Pharmacol Ther; 1999 Sep; 13(9):1215-9. PubMed ID: 10468704
[TBL] [Abstract][Full Text] [Related]
8. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
10. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline.
Kokufu T; Ihara N; Sugioka N; Koyama H; Ohta T; Mori S; Nakajima K
Eur J Clin Pharmacol; 1995; 48(5):391-5. PubMed ID: 8641328
[TBL] [Abstract][Full Text] [Related]
11. High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies.
Pandya KK; Mody VD; Satia MC; Modi IA; Modi RI; Chakravarthy BK; Gandhi TP
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):199-204. PubMed ID: 9200535
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
13. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
Harder H; Teyssen S; Stephan F; Pfützer R; Kiel G; Fuchs W; Singer MV
Scand J Gastroenterol; 1999 Jun; 34(6):551-61. PubMed ID: 10440603
[TBL] [Abstract][Full Text] [Related]
14. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers.
Jovanović D; Kilibarda V; Maksimović M
Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
Mainz D; Borner K; Koeppe P; Kotwas J; Lode H
J Antimicrob Chemother; 2002 Nov; 50(5):699-706. PubMed ID: 12407126
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between acetaminophen and lansoprazole.
Sanaka M; Kuyama Y; Mineshita S; Qi J; Hanada Y; Enatsu I; Tanaka H; Makino H; Yamanaka M
J Clin Gastroenterol; 1999 Jul; 29(1):56-8. PubMed ID: 10405233
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
18. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans.
Katsuki H; Yagi H; Arimori K; Nakamura C; Nakano M; Katafuchi S; Fujioka Y; Fujiyama S
Pharm Res; 1996 Apr; 13(4):611-5. PubMed ID: 8710755
[TBL] [Abstract][Full Text] [Related]
19. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
20. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
